ResGuard Med monitors symptoms at night.
Automatically and passively.
In times of medical necessity, we will alert you.
No risk, no alerts.
We enrich your subjective disease assessments.
With objective facts.
Zurich, Switzerland, January 19th, 2021 – Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device. ...
The jury of Venture Leaders Mobile 2021 selected 10 start-ups. They represent a range of sectors from digital health to insurtech and advance innovations in artificial intelligence, big data, or blockchain. The selected teams will travel to Barcelona to attend the Mobile World Congress from June 28–July 1, 2021, planned as an in-person event with hybrid experiences.
Resmonics win Venture Kick's final stage of financial and entrepreneurial support. Their first product, ResGuard Med, is a CE-certified early-warning system that helps patients with chronic respiratory diseases manage their condition.
Head of Product Management
Senior iOS Developer